Filter by:
Muscular Dystrophy
March 2025
2025 MDA Annual Clinical and Scientific Conference
Improved Plasma Signature of Contraction-Induced Muscle Injury with Sevasemten in Becker Muscular Dystrophy in the CANYON Phase 2 Trial
Muscular Dystrophy
March 2025
2025 MDA Annual Clinical and Scientific Conference
CANYON Trial Results: Sevasemten, an Investigational Fast Skeletal Myosin Inhibitor, Reduced Muscle Damage Biomarkers and Stabilized Function in BMD
Cardiovascular
December 2024
Global CVCT Forum
Hypertrophic Cardiomyopathies – New Challenges for Future Trials
Cardiovascular
December 2024
Global CVCT Forum
EDG-7500, a First-in-Class Cardiac Sarcomere Modulator, Demonstrates Favorable Tolerability, Safety, and Pharmacokinetics in Healthy Adults and Patients with Hypertrophic Cardiomyopathy
Cardiovascular
November 2024
American Heart Association Scientific Sessions 2024
Chronic administration of EDG-7500, a novel sarcomere modulator, prevents increases in cardiac mass, T1 relaxation time, and left ventricular end diastolic pressure in a Yucatan mini-pig model of genetic non-obstructive hypertrophic cardiomyopathy
Muscular Dystrophy
October 2024
World Muscle Society 2024
